



Global Burden of Cervical Cancer

VANCOUVER, April 21, 2021 – Medmelior Pharma Inc. (“Medmelior”) an emerging private biotech company focused on the development and refinement of drug candidates from a broad set of complementary interferon-based technologies.

This report indicates that “HPV is responsible for malignancy and mortality in women across the world and has claimed the lives of thousands of women.”

The comprehensive report can be found read at: [Intechopen](#).

About Medmelior Pharma

Medmelior Pharma Inc. is an emerging private biotech company focused on the development and refinement of drug candidates from a broad set of complementary interferon-based technologies. It has two highly prospective and powerful drugs for treatment of viral Infections: MM-001 for the treatment of HPV and MM-003 for the treatment of viral respiratory infections.

For further information, please visit [Medmelior Pharma](#).

Contact Information

Dr. Ahmad Doroudian

Email: info@medmelior.com

Cautionary Note Regarding Forward-Looking Statements

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will,” “may,” “should,” “anticipate,” “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove

to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.